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Background: A community-based antiretroviral therapy (ART) programme was estab-
lished in 2001 in a South African township to explore the operational issues involved
in providing ART in the public sector in resource-limited settings and demonstrate the
feasibility of such a service.
Methods: Data was analysed on a cohort of patients with symptomatic HIV disease
and a CD4 lymphocyte count , 200 3 106 cells/l. The programme used standardized
protocols (using generic medicines whenever possible), a team-approach to clinical
care and a patient-centred approach to promote adherence.
Results: Two-hundred and eighty-seven adults naive to prior ART were followed for a
median duration of 13.9 months. The median CD4 lymphocyte count was 43 3 106
cells/l at initiation of treatment, and the mean log10 HIV RNA was 5.18 copies/ml. The
HIV RNA level was undetectable (, 400 copies/ml) in 88.1, 89.2, 84.2, 75.0 and
69.7% of patients at 3, 6, 12, 18 and 24 months respectively. The cumulative
probability of remaining alive was 86.3% at 24 months on treatment for all patients,
91.4% for those with a baseline CD4 lymphocyte count > 50 3 106 cells/l, and
81.8% for those with a baseline CD4 lymphocyte count , 50 3 106 cells/l. The
cumulative probability of changing a single antiretroviral drug by 24 months was
15.1% due to adverse events or contraindications, and 8.4% due to adverse events
alone.
Conclusions: ART can be provided in resource-limited settings with good patient
retention and clinical outcomes. With responsible implementation, ART is a key
component of a comprehensive response to the epidemic in those communities most
affected by HIV. & 2004 Lippincott Williams & Wilkins
AIDS 2004, 18:887–895
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Introduction
The beneﬁts of antiretroviral therapy (ART) at an
individual level are incontrovertible [1,2]. The poten-
tial beneﬁts at a population level of successful ART
programmes in those countries worst affected by the
HIV pandemic are widely argued [3,4]. Even where
universal access to ART for those who could beneﬁt
from it is not possible, many have argued strongly for
ART to be an important component of an integrated
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[3,5].
The publication by the World Health Organization
(WHO) of guidelines for the scaling up of antiretroviral
therapy in resource-limited settings [6] signals a con-
vergence of clinical thinking that should, in theory,
facilitate the rapid expansion of ART in these settings.
Evidence of the effectiveness of public sector ART
programmes in those countries with the largest HIV-
morbidity and mortality burdens has, however, been
slow in emerging. Many interventions have relied on
private or out-of-pocket funding of treatment, [7] and
where policies exist to provide treatment in the public
sector, uptake has been slower than anticipated [8].
The aim of this analysis is to present the early clinical
outcomes for adults in a public-sector ART pro-
gramme in a primary care setting in a poor urban
community in South Africa.
Methods
Setting
Khayelitsha is a township with an estimated population
of 400000 [9]. Housing is both formal and informal.
Most residents rely on health services delivered by the
state, with unemployment levels considerably higher
that the national average [10]. The HIV-1 seropreva-
lence in public-sector antenatal clinics in this health
district in 2002 was 24.9% [11]. Tuberculosis incidence
in 2001 was 1062 per 100000 [12]. In 1999, the ﬁrst
routine programme in South Africa to prevent the
transmission of HIV from mother to child was initiated
at the two health centres in Khayelitsha that provide
maternity services [13]. Dedicated services for adults
and children with HIV were established in April 2000
through a collaboration between the provincial govern-
ment and the international non-governmental organi-
zation (NGO) Me ´decins Sans Frontie `res (MSF). Three
dedicated HIV/AIDS clinics were opened within
Khayelitsha’s community health centres providing a full
package of prophylaxis and treatment of opportunistic
infections. In May 2001, the HIV/AIDS clinics began
to offer ART. Patients receive ART free of charge.
MSF provides the antiretroviral medicines, the HIV
RNA tests, and half of the clinical staff, whilst the
remaining costs are carried by the provincial govern-
ment. The study has ethical approval from the South
African Medical Association. By the end of July 2003,
over 600 adults and children had started ART as part
of the programme.
Patient preparation and selection
Selection criteria required that patients be symptomatic
(WHO clinical stage III or IV [14]) and have a CD4
lymphocyte count of , 200 3 106 cells/l. Patients
were required to meet a number of additional criteria
including: nominating a ‘treatment assistant’ to assist
with adherence; receiving a home-visit to verify the
family environment, evidence of disclosure and that the
patient was indeed resident in Khayelitsha; and, atten-
dance on time for at least three previous appointments
over a minimum of 4 months. Each candidate’s folder
was anonymously presented to a community selection
committee.
Clinical services and regimens
Clinical services are provided in each of the three
clinics by a team comprising a doctor, two nurses and
two counsellors, with good continuity of care. Reason-
able referral networks exist with local hospitals and
other primary care services such as tuberculosis services.
The consultation frequency for those on ART is
determined by the clinical protocol; weekly for the ﬁrst
2 weeks, then fortnightly until 2 months on ART,
monthly until the ﬁrst year on ART, and 2–3-monthly
thereafter. Patients are seen more frequently if clinically
indicated. Doctors are mainly responsible for treatment
initiation, regimen changes and dealing with speciﬁc
problems, whilst nurses provide most of the routine
patient follow-up for those on ART according to
standardized protocols. Plasma HIV RNA measure-
ments are performed at baseline, 3 and 6 months, and
CD4 lymphocyte counts are carried out at baseline and
6 months. Both tests are conducted 6-monthly there-
after. Standardized ﬂowchart algorithms for the man-
agement of adverse events and virological failure guide
doctors and nurses in safety monitoring and when and
how to change treatment.
The clinical protocol stipulates that patients begin
treatment on zidovudine, lamivudine and either efavir-
enz or nevirapine. Generic zidovudine, lamivudine, a
ﬁxed dose combination of zidovudine and lamivudine,
and nevirapine were all procured from the Brazilian
state manufacturer FarManguinhos under a compassio-
nate use agreement with the South African Medicines
Control Council. The remaining antiretroviral drugs
that were used were all fully registered with the
Medicines Control Council.
A strong patient-centred approach is used to promote
adherence. This includes a comprehensive counselling
infrastructure providing for one-on-one individual
counselling with trained lay-counsellors, and regular
support groups. A treatment access NGO, the Treat-
ment Action Campaign, is active in all three of the
clinics, and their activities contribute to the treatment
literacy of patients.
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All adult patients naive to prior ART who started
antiretroviral treatment between 29 May 2001 and 31
December 2002 were included in the analysis. Mothers
who had received up to 1 month of zidovudine
antenatally for the prevention of mother-to-child trans-
mission were included. Patients were considered non-
naive and were excluded from the study if they had
received more than 1 month of ART as treatment
prior to joining the programme. The cohort is ordered
and analysed by duration on treatment.
CD4 lymphocyte counts were performed by ﬂow-
cytometry. Plasma HIV RNA levels were measured
using the nucleic acid sequence-based ampliﬁcation
procedure (NASBA) Nuclisens HIV-1 QT assay (Bio-
Merieux, Boxtel, the Netherlands).
Product-limit estimates (Kaplan–Meier) of survival were
determined for all patients irrespective of subsequent
discontinuation of therapy. Patients alive and in care on
31 July 2003 were right-censored on the date of their last
visit prior to this date. Patients who had not attended
services for 3 months or more beyond their last scheduled
appointment and who could not be traced were classiﬁed
as being lost to follow-up and statistically were consid-
ered as deaths on their last recorded visit to the clinics.
Patients who had ceased attending the clinic but were
known to be alive on 31 July 2003 were right-censored
on their last visit to the clinic, as were those patients who
negotiatedtheirtransfertoadifferentprovince.Thesame
analysiswas repeatedstratiﬁedbyinitialCD4lymphocyte
count category, with the log-rank test used to compare
survival between the two groups. Cox proportional
hazards regression was used to calculate univariate and
adjusted hazard ratios (AHR) and conﬁdence intervals
(CI)forsurvival fora numberof variables.
Other outcomes included median changes in absolute
CD4 lymphocyte counts and the percentage of patients
with plasma HIV-RNA measurements , 400 copies/
ml at various durations on treatment. Baseline labora-
tory tests were considered valid if performed within
1 year prior to the initiation of therapy, although most
fell within the month prior to ART initiation. Subse-
quent laboratory outcomes were allocated to the
appropriate durations on treatment for all patients on
ART at the time of the investigation. A single HIV
RNA > 400 copies/ml at any duration on treatment
was recorded as being above this value, whilst in
instances where HIV RNA measurements were re-
peated in short succession to conﬁrm elevated levels,
and were subsequently found to be below this value,
the result for that duration on treatment was recorded
as being , 400 copies/ml.
Estimates of the percentage of patients changing treat-
ment were calculated as product-limit estimates.
Weight changes were calculated as median increases
compared to baseline.
An independent analysis of cause of death developed a
functional classiﬁcation of cause based on data available
in the clinical records held at the primary care level for
those patients for whom sufﬁcient data was available.
Analyses were performed using STATA software (ver-
sion 8.0; Stata Corp., College Station, Texas, USA).
Results
The analysis included 287 adults started on ART
(Table 1). One patient was excluded from the analysis
due to prior ART. The median follow-up time
was 14.9 months for those surviving after starting
ART, and 13.9 months for all patients. More women
than men accessed treatment (70%). Patients began
treatment with advanced disease–the median CD4
lymphocyte count at baseline was 43 3 106 cells/l
[interquartile range (IQR), 13–94 3 106 cells/l], with
52% having a prior AIDS diagnosis. These character-
istics did not change signiﬁcantly over the enrolment
period. The mean HIV RNA on initiation of treatment
was 5.18log10 copies/ml [standard deviation (SD)
0.68log10 copies/ml]. Sixty per cent of patients began
treatment on zidovudine, lamivudine and efavirenz,
and 38% on zidovudine, lamivudine and nevirapine
(Table 1).
Survival and patient retention
One patient was lost to follow-up soon after commen-
cing treatment. An additional six patients had stopped
ART at the time of the analysis but were still attending
services. Three patients had transferred to other pro-
vinces, and three patients had stopped attending the
clinics but were conﬁrmed to still be alive on the 31
July 2003.
Thirty-eight patients died after starting ART. All
except two deaths were attributed to HIV, and oc-
curred before 12 months of follow-up (71% before 3
months duration on ART), yielding a product-limit
estimate of survival at 24 months of 86.3% (95% CI,
81.7–89.8%) (Fig. 1). One-hundred and ﬁfty-ﬁve pa-
tients (55%) began treatment with a CD4 lymphocyte
count of , 50 3 106 cells/l. Estimates of survival at 24
months stratiﬁed by initial CD4 lymphocyte count
were 81.8% (95% CI, 74.7–87.0%) for those initiating
treatment with a CD4 lymphocyte count , 50 3 106
cells/l and 91.4% (95% CI, 84.9–95.1%) for those with
initial CD4 lymphocyte counts . 50 3 106 cells/l (P ¼
0.0171) (Fig. 2).
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survival (Table 2), CD4 lymphocyte count (categorical
variable as described above) and a diagnosis of Kaposi’s
sarcoma (n ¼ 16) were found to be signiﬁcantly asso-
ciated with outcome (Table 2)—the AJR of death or
loss to follow-up was 2.41 (95% CI, 1.20–4.87) for
those in the lower initial CD4 lymphocyte count
category compared to the higher category, and 4.82
(95% CI, 2.12–10.97) for a previous diagnosis of
Kaposi’s sarcoma.
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Fig. 1. Survival of adults on antiretroviral treatment.
Table 1. Characteristics and starting regimens of patients beginning antiretroviral therapy.
All patients n ¼ 287a
Median age [years (IQR)] 31 (28–37)
Female [n (%)] 201 (70%)
CD4 lymphocyte count at baseline (3 106 cells/l)
Median (IQR) 43 (13–94)
Count , 50 3 106 cells/l [n (%)] 155 (55)
Prior AIDS diagnosis
AIDS diagnosis (%) 148 (52)
Follow-up time (months)
Median for all patients (IQR) 13.9 (9.2–18.1)
Median for those surviving (IQR) 14.9 (11.0–19.5)
HIV RNA level at baseline (log10 HIV RNA copies/ml)
Mean (SD) 5.18 (0.68)
Initial antiretroviral regimen
ZDV/3TC/EFV [n (%)] n ¼ 173 (60)
ZDV/3TC/NVP [n (%)] n ¼ 108 (38)
ZDV/3TC/IDV (  RTV) (%) n ¼ 4
d4T/3TC/NVP (%) n ¼ 1
d4T/3TC/EFV (%) n ¼ 1
aA baseline CD4 lymphocyte count was unavailable for three patients (n ¼ 284) and a baseline
HIV RNA level was unavailable for 16 patients (n ¼ 271). IQR, Interquartile range; SD, standard
deviation; ZDV, zidovudine; 3TC, lamivudine; NVP, nevirapine; IDV, indinavir; RTV, ritonavir;
d4T, stavudine; EFV, efavirenz.
AIDS 2004, Vol 18 No 6 890In the review of cause of death, 20 deaths were
classiﬁed as being due to very advanced disease at the
time of starting ART, with continued deterioration on
treatment. None of these deaths were thought by the
reviewer to be attributable to immune-reconstitution
disease. The median CD4 lymphocyte count in this
group was 7 3 106 cells/l (IQR, 4–25 3 106 cells/l),
and the median duration on treatment when they died
was 21 days (IQR, 14–31 days). Three patients died as
a result of tuberculosis (duration on ART of 6, 145 and
241 days), and three from probable Kaposi’s sarcoma
(duration on ART of 45, 70 and 79). One patient died
after 104 days on ART due to intractable cytomegalo-
virus colitis that predated ART. Six patients experi-
enced disease progression due to treatment interruption
or documented poor adherence. The non-HIV related
deaths included a 29-year-old woman with underlying
mitral stenosis who died of a cerebrovascular insult 7
months after starting ART, and a 46-year-old man
with a squamous cell carcinoma of the lung who died 9
months after starting ART. No deaths were attributed
to antiretroviral treatment.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Duration of treatment (months)
0 3 6 9 12 15 18 21 24
0.75
0.80
0.85
0.90
0.95
1.00
At risk
Deaths &
loss to follow-up
Survival (%)
95% CI
Baseline CD4
(  106 cells/l)
  50
  50
  50
  50
  50
  50
129
155
90.9–98.4
123
133
5
23
96.1
78.5–89.9
85.2
119
132
4
2
93.0
86.9–96.3
83.9
77.1–88.8
84.9–95.1
109
109
2
2
91.4
75.6–87.7
82.5
84.9–95.1
84
82
0
1
91.4
74.7–87.0
81.8
84.9–95.1
57
66
0
0
91.4
74.7–87.0
81.8
84.9–95.1
34
41
0
0
91.4
74.7–87.0
81.8
84.9–95.1
23
33
0
0
91.4
74.7–87.0
81.8
84.9–95.1
13
22
0
0
91.4
74.7–87.0
81.8
CD4 lymphocyte count  50   106 cells/l
CD4 lymphocyte count   50   106 cells/l
P   0.0171
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
Fig. 2. Survival of adults on antiretroviral treatment stratiﬁed by initial CD4 lymphocyte count.
Table 2. Cox proportional hazards models of potential associations between baseline characteristics of patients and survival.
Univariate analysis Multivariate analysis
Hazard ratio for death
(95% CI) P
Hazard ratio for death
(95% CI) P
Baseline CD4 lymphocyte count ( 3 106 cells/l) 2.28 (1.13–4.58) 0.021 2.41 (1.20–4.87) 0.013
Baseline HIV RNA (log10 copies/ml) 1.2 (0.73–1.96) 0.456 – –
AIDS diagnosis 1.26 (0.67–2.38) 0.468 – –
Kaposi’s sarcoma 4.48 (1.97–10.17) , 0.001 4.82 (2.12–10.97) , 0.001
Choice of NNRTI nevirapine 0.52 (0.25–1.07) 0.079 – –
Age in years 1 (0.96–1.04) 0.795 – –
Male sex 1.92 (1.02–3.63) 0.042 – –
Outcomes after two years of antiretroviral treatment in South Africa Coetzee et al. 891Other clinical outcomes
The median weight gain at 6 months on treatment was
5.0 kg (IQR, 1.5–9.6 kg) and 9.0 kg (IQR, 4.0–
14.3 kg) at 12 months. The percentage of patients with
HIV RNA measurements , 400 copies/ml (Fig. 3) was
maximal at 6 months (89.2%; 95% CI, 84.4–92.9%),
with 84.2% (95% CI, 77.5–89.5%) of patients still
having measurements within this range at 12 months,
and 69.7% (95% CI, 51.3–84.4%) at 24 months.
The CD4 lymphocyte count increased rapidly com-
pared to the pre-treatment level in the ﬁrst 6 months
on treatment (Fig. 3), increasing by a median of 134 3
106 cells/l (IQR, 76–206 3 106 cells/l). Although the
gain in CD4 lymphocyte count in subsequent intervals
was lower than this, by 24 months on ART the median
increase in CD4 lymphocyte count compared to base-
line was 288 3 106 cells/l (95% CI, 181–470 3 106
cells/l), with a median absolute CD4 lymphocyte count
at this duration on treatment of 323 3 106 cells/l.
Regimen durability
The highest percentage of changes in regimen (Table 3)
le 3) due to adverse events attributed to an individual
antiretroviral was for nevirapine for which 8.8% (95%
CI, 4.8–15.8%) (product-limit estimate) of patients had
changed to efavirenz at 24 months. The equivalent
percentage for zidovudine was 4.7% (95% CI, 2.6–
8.0%) of patients changing to stavudine. No patients
were changed from lamivudine for any agent-speciﬁc
reason, and only two patients could not tolerate
efavirenz. For all regimens combined, 8.4% (95% CI,
5.6–12.5%) of patients had an intolerance-driven
change to their ﬁrst regimen cumulatively by 24
months. Most changes occurred soon after treatment
was started (median 42 days; IQR, 28–56 days). A
further 10 patients switched from nevirapine to efavir-
enz due to a new episode of tuberculosis as efavirenz
was the only non-nucleoside reverse transcriptase in-
hibitor recommended for co-administration with rifam-
picin, [15] and three patients from efavirenz to
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Fig. 3. Laboratory outcomes by duration of treatment.
Table 3. Changes to the initial treatment regimen.
Zidovudine Nevirapine Efavirenz All
Number ever to start on antiretroviral 285 114 197 288
Number changed due to side-effects 12 10 2 23
Time to change in days [median (IQR)] 53 (35–74) 20 (15–42) day 8 & 262 42 (28–56)
Changed by 24 months [% (95% CI)]a 4.7 (2.6–8.0) 8.8 (4.8–15.8) 1.2 (0.3–4.9) 8.4 (5.6–12.5)
Changed due to contraindications (n) 0 10b 3c 13
aProduct limit estimate for those changing due to side-effects. bChanged due to a new episode of tuberculosis. cChanged due to pregnancy or
desire for pregnancy. IQR, Interquartile range; CI, conﬁdence interval.
AIDS 2004, Vol 18 No 6 892nevirapine due to pregnancy or a wish to become
pregnant. Including these latter switches, 15.1% (95%
CI, 10.7–21.1%) of patients on the ﬁrst-line regimen
had a regimen change due to adverse events or contra-
indications by 24 months. Twelve patients had changed
the entire regimen due to treatment failure by the end
of July 2003.
Discussion
This analysis is limited by the short duration of
follow-up and by the small numbers at risk in the
analysis beyond 1 year on treatment. The early results
of this programme are, however, comparable with data
from observational settings in both developed and
developing countries. This programme builds on
results reported for other African settings in demon-
strating the feasibility of successful ART programmes
in these contexts [7,16]. In spite of differences in
reporting, patients in Khayelitsha initiated therapy
with more advanced disease than reported in Uganda
[7] and Senegal, [16] and using survival as an end-
point, have responded to treatment at least as well, if
not better. Furthermore, this programme represents
one of the ﬁrst attempts to integrate ART as part of a
comprehensive government response to HIV/AIDS in
a geographically-deﬁned health district. Previous work
in Cape Town indicates that median survival without
ART for those with CD4 lymphocyte counts
, 50 3 106 cells/l would be less than 12 months [17].
This highlights the likely beneﬁt of the intervention
in this population where the survival estimate for the
same subgroup of patients at 12 months duration on
ART was 81.8%.
Survival outcomes in this programme are comparable
to those reported for patients initiating ART with very
low CD4 lymphocyte counts in two observational
studies in Canada and the USA [18]. Although the
observation periods for these cohorts include years
where dual therapy was provided, the point estimates
of survival are very similar to those observed in
Khayelitsha, ranging from 64.6% to 79.5% for those
initiating treatment with CD4 lymphocyte counts
, 50 3 106 cells/l, and from 78.1% to 90.0% for those
initiating treatment with CD4 lymphocyte counts
above this value. At 24 months duration on treatment
the stratiﬁed survival estimates from Khayelitsha exceed
the upper end of these ranges.
In many of those countries worst affected by the HIV
pandemic, scarcity of resources and capacity will mean
that not everyone with the potential to beneﬁt from
ART will be able to access it, with a tendency for the
sickest patients to access treatment ﬁrst. The difference
in survival in the Khayelitsha cohort between those
starting treatment with CD4 lymphocyte counts of
50 3 106 cells/l or more compared to the group with
CD4 lymphocyte counts below this level, suggests that
one of the major challenges in contexts such as
Khayelitsha is to ensure a fair balance between provid-
ing access to ART for those presenting very late, whilst
preserving the opportunity for a better prognosis for
those who have enrolled in the programme in a timely
manner. Given that survival in those presenting with
CD4 lymphocyte counts , 50 3 106 cells/l is never-
theless markedly improved compared to the anticipated
natural history, the programme does not consider CD4
lymphocyte count an exclusion to ART if the Karnofs-
ky score is above 40%. It may in future be possible to
identify strategies to further improve survival in this
early period for those with extensive immune suppres-
sion at presentation.
The stratiﬁcation of survival by a CD4 lymphocyte
count of 50 3 106 cells/l was motivated by the poten-
tial to compare to other studies that have used these
categories. However, the data suggested that the
survival experience in this context would be more
powerfully discriminated by a dichotomous categoriza-
tion at a lower CD4 lymphocyte count.
The exploration of an association of a previous diag-
nosis of Kaposi’s sarcoma (KS) with survival was
prompted by reports of an association in other MSF
projects. A mortality review suggested that in only
three out of eight cases could the cause of death be
directly linked to KS. Clinical details of the nature and
extent of KS were not available. A more thorough
exploration of this association is warranted as the
numbers on treatment in the project increase. Although
only three deaths were linked to new episodes of
tuberculosis following initiation of ART, tuberculosis
poses constant challenges in this setting. A full inci-
dence study of tuberculosis prior to ART and on ART
is currently underway. Innovative approaches to mana-
ging tuberculosis that extend beyond the provision of
ART are urgently required. The occurrence of a
number of deaths very soon after initiating treatment is
most likely due to the extreme disease advancement of
many patients by the time they were able to access
treatment.
The high proportion of patients with HIV RNA
measurements , 400 copies/ml in the ﬁrst year on
treatment further underpins the fact that adherence
rates, comparable to those in rich countries, are achiev-
able in resource-limited settings [19]. The proportions
of patients with HIV RNA measurements , 400 co-
pies/ml at various durations on treatment compare
favourably with those reported in other African set-
tings, [7,16] and are similar to those from rich countries
in spite of differences in reporting [20–22]. CD4
lymphocyte count gains were impressive and are similar
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elsewhere, [23] in spite of the relatively late initiation
of treatment.
Although this paper has not sought to explore the costs
of treatment, at $60 (USD 1 ¼ ZAR 8) per test, HIV
RNA testing is a signiﬁcant expense to the programme
relative to drug costs. A generic triple-therapy regimen
was being purchased at the end of 2002 for $1.08 per
day. This highlights the importance of campaigning for
lower prices of HIV RNA testing together with
antiretroviral drugs, or of validating approaches that do
not include HIV RNA testing.
Rates of treatment change due to adverse events were
uniformly low, and comparable or lower than those
published for other cohorts [24]. This is a reﬂection of
the incidence of severe adverse events in general, and
demonstrates that with standardized regimens, monitor-
ing and clinical management algorithms as is the case in
Khayelitsha, ART can be safely used in resource-
constrained settings. The most common contraindica-
tion resulting in a treatment change was in patients
who developed tuberculosis after starting ART and
who were switched from nevirapine to efavirenz, due
to concerns about the co-administration of nevirapine
with rifampicin.
With the recent declaration by the WHO of the
failure to deliver AIDS medicines to those who need
them as a global health emergency, exploring the
programme design choices that impact on clinical
outcomes in developing countries is urgent. There are
a number of important lessons emerging from this
programme. Careful preparation of patients is essential,
extending beyond applying clinical eligibility criteria.
This, together with treatment in a primary care
setting, and as part of an integrated package of services
for HIV, maximizes the potential impact of treatment
programmes. With a patient-centred approach and a
strong support programme involving speciﬁcally
trained lay counsellors and peer support mechanisms,
good adherence to treatment is achievable. With
support, nurses can diagnose and treat most opportu-
nistic infections and deliver ART in line with standar-
dized protocols.
Although there are a number of factors that have
promoted programme success, including the involve-
ment of an international NGO, most treatment advo-
cates would envisage new resources accompanying the
introduction of ART in resource-constrained settings.
Khayelitsha represents one of the most marginalized
urban communities in South Africa, with extensive co-
morbidity and health-system challenges. These ﬁndings
provide encouragement to those seeking to provide
similar services in poor communities where HIV
morbidity and mortality are high.
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